Categories Earnings, Health Care

Novavax beats Q1 revenue estimates while earnings come in line

Novavax Inc. (NASDAQ: NVAX) topped market estimates on revenue for the first quarter of 2019 while earnings matched expectations. Analysts had forecasted a loss of $0.11 per share on revenue of $3.94 million. Shares gained 2.4% in aftermarket hours on Thursday.

Total revenue of $4 million was down 59% year-over-year, driven by the completion of enrollment of the Prepare trial in the second quarter of 2018.

The company reported a net loss of $43.2 million, or $0.11 per share, compared to $46.4 million, or $0.14 per share, in the year-ago quarter.

Novavax reports first quarter 2019 results
For representational purposes only. (Image courtesy: Paweł Czerwinski/Unsplash)

R&D expenses decreased 20% to $35.5 million, mainly due to decreased development activities, including lower clinical trial costs, of ResVax.

Novavax plans to meet with the FDA, European regulatory agencies, and potentially other national regulatory agencies during the second and third quarters of the year to assess opportunities for the submission of marketing applications for ResVax.

The company is also looking to reach an agreement with the FDA during the third quarter of 2019 on a proposed Phase 3 clinical trial design for NanoFlu utilizing accelerated approval criteria for licensure.

As of March 31, 2019, Novavax had $108.7 million in cash, cash equivalents, marketable securities and restricted cash.

On April 11, 2019, Novavax received a warning notice from Nasdaq saying that the stock could be delisted as the company’s stock fell below $1 for 30 consecutive days. The stock has to close at $1.00 or higher for a minimum of ten consecutive business days during the 180-day compliance period to avoid delisting and if this doesn’t happen by October 8, 2019, Nasdaq will be sending a delisting notice to Novavax.

Also Read:  McKesson Corp. (MCK) Q1 2021 Earnings Call Transcript

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Biocept (BIOC) revenue drops 23% in Q2; loss narrows

Biocept (NASDAQ: BIOC) reported a narrower loss in the second quarter of 2020. The company's revenue declined by 23% year-over-year to $917,000, hurt by the COVID-19 pandemic. BIOC stock slumped

Lyft rides home better-than-expected results in Q2

Lyft Inc (NASDAQ: LYFT) reported second-quarter financial results after the closing bell on Wednesday. The ride-hailing company reported a 61% dip in Q2 revenues to $339.3 million, narrowly beating Wall

Cisco Systems (CSCO) Q4 earnings drop but top expectations

https://www.youtube.com/watch?v=AFttiM-lTuY&t=138s Network gear maker Cisco Systems, Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the fourth quarter of fiscal 2020, reporting a decline in earnings and revenues. However, the

Top